arrow
M

Min-Su Kang

seoul national university (snu)
H指数:22
被引数:1,764

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Pilot Study for Feasibility of Onco-Geriatric Intervention Model in Older Patients with Cancer in a Tertiary Academic Hospital

在三级教学医院中针对老年癌症患者开展肿瘤-老年干预模型的可行性初步研究

2026-01-010
OA
Durvalumab in Advanced Biliary Tract Cancer: Real-World Data From a Large Cohort of Patients Across Multiple International Centers

度伐利尤单抗在晚期胆道癌中的应用:来自多个国际中心大型患者队列的真实世界数据

2025-11-120
OAAI
Genomic Pathway Alterations and Their Prognostic Impact in Biliary Tract Cancer: Insights from a Multinational Cohort Treated with Cisplatin, Gemcitabine, and Durvalumab

基因组通路改变及其在胆道癌中的预后影响:来自接受顺铂、吉西他滨和度伐利尤单抗治疗的跨国队列的见解

2025-10-030
PRE
The impact of molecular alterations in patients with advanced biliary tract cancer receiving cisplatin, gemcitabine, and durvalumab: a large, real-life, worldwide population

接受顺铂、吉西他滨和度伐利尤单抗治疗的晚期胆道癌患者中分子改变的影响:一项大型、真实世界、全球性人群研究

2025-09-011
PRE
Early growth response 1 as a key regulator of PD-L1 expression and immune evasion in extranodal NK/T-cell lymphoma

早期生长反应1作为PD-L1表达和免疫逃逸的关键调节因子在结外NK/T细胞淋巴瘤中的作用

2025-06-130
OAAI
Association of candidate surrogate endpoints with overall survival in advanced biliary tract cancer

候选替代终点与晚期胆道癌总生存率的关系

2025-06-030
PRE
Pairwise analysis of plasma cell-free DNA before and after palliative second-line paclitaxel plus ramucirumab treatment in patients with metastatic gastric cancer

转移性胃癌患者接受姑息性二线紫杉醇联合雷莫芦单抗治疗前后血浆游离DNA的配对分析

2025-03-270
OA
Association of TP53 Mutation Status and Sex with Clinical Outcome in Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors: A Retrospective Cohort Study

TP53突变状态与性别对接受免疫检查点抑制剂治疗的非小细胞肺癌患者临床结局的影响:一项回顾性队列研究

2025-01-151
OA
Second-Line Fluoropyrimidine-Based Chemotherapy in Advanced Biliary Tract Cancer: A Meta-analysis Based on Individual Patient-Level Data of Randomized Trials

二线以氟嘧啶为基础的化疗在晚期胆道癌中的应用:一项基于随机试验个体患者数据的Meta分析

2024-10-170
OA
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide population

Durvalumab联合吉西他滨和顺铂治疗晚期胆道癌: 大量现实世界人口

2024-09-013
PRE
Real-world outcomes of third-line immune checkpoint inhibitors versus irinotecan-based chemotherapy in patients with advanced gastric cancer: a Korean, multicenter study (KCSG ST22-06)

在晚期胃癌患者中,三线免疫检查点抑制剂与基于伊立替康的化疗的真实世界结果: 韩国多中心研究 (KCSG ST22-06)

2024-02-232
OAAI